WhiteSpace Enterprises Corporation (WSE) Was born out of pioneering research started in 2005 at Arizona State University and the University of Arizona College of Medicine in Phoenix that defined the concept of Rapid DNA analysis for forensics. Rapid DNA analysis is now emerging as the next step in human identification for criminal investigation as it allows to process DNA samples such as buccal swab in considerably less amount of time, at a lower cost, and in an automated fashion using Micro Total Analysis (MicroTAS) or lab-on-a-chip microfluidic technology.
The research resulted in a strong patent portfolio and several highly-cited research papers (e.g. Analytical Chemistry 2010, 82, 6691-6699 or Forensic Sci. Int. 2014, 8, 147-158). More importantly, it delivered a self-contained modular monolithic microfluific technology and expertise that does not require external pumping or valving. WSE uses this technology now to propose different sample processing and analysis detection platforms for point-of-care applications in many areas beyond forensic DNA identification from life sciences to personalized medicine. WSE holds about a dozen patents filed in global geographic regions. WSE has also several pending grants and contracts with U.S. federal government agencies, global private corporations and research contractors.
Today WSE is expending its domain of innovation with groundbreaking approaches that can access unobtrusively biological samples readily available and critical to any molecular test, and develop technological components integrating the analytical workflow process suitable for remote and mobile medical care services and solutions.
WSE has the knowledge and engineering capital for leading the transformation of a more translational and omics-based healthcare delivery system. Transformation will be accelerated by developing simpler tests using engineering fundamentals of miniaturization and integration, provided easier and less invasive access to biological specimen of individuals that can be monitored in real-time generating a personalized phenotype of molecular fingerprints whose signatures may guide earlier care for effectively intervening with more precise treatment approaches for high value outcomes.